Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells
Authors
Keywords
-
Journal
Nature Biomedical Engineering
Volume 5, Issue 11, Pages 1288-1305
Publisher
Springer Science and Business Media LLC
Online
2021-09-28
DOI
10.1038/s41551-021-00797-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species
- (2020) Ufuk Karakus et al. Science Translational Medicine
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
- (2020) Dilara Sahin et al. Nature Communications
- Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
- (2019) Jing He et al. ANNALS OF THE RHEUMATIC DISEASES
- Effects of interleukin-2 in immunostimulation and immunosuppression
- (2019) Jonathan G. Pol et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity
- (2019) Jun-Young Lee et al. OncoImmunology
- Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells
- (2018) Tania Carmenate et al. JOURNAL OF IMMUNOLOGY
- Regulatory T cells in autoimmune disease
- (2018) Margarita Dominguez-Villar et al. NATURE IMMUNOLOGY
- A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism
- (2018) Eleonora Trotta et al. NATURE MEDICINE
- Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
- (2018) Jonathan T. Sockolosky et al. SCIENCE
- Targeting B Cells and Plasma Cells in Autoimmune Diseases
- (2018) Katharina Hofmann et al. Frontiers in Immunology
- Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy
- (2018) Jamie B. Spangler et al. JOURNAL OF IMMUNOLOGY
- Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
- (2018) Michelle Rosenzwajg et al. ANNALS OF THE RHEUMATIC DISEASES
- Natural and modified IL-2 for the treatment of cancer and autoimmune diseases
- (2018) Masayuki Mizui CLINICAL IMMUNOLOGY
- A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
- (2018) Laurence B. Peterson et al. JOURNAL OF AUTOIMMUNITY
- IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells
- (2018) Natasha C. Ward et al. JOURNAL OF IMMUNOLOGY
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
- (2017) Ling Wu et al. JOURNAL OF CONTROLLED RELEASE
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2
- (2016) Connor J. Dwyer et al. Current Diabetes Reports
- Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
- (2016) Nayoun Kim et al. CYTOKINE
- Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
- (2016) Jing He et al. NATURE MEDICINE
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Low-Dose IL-2 in the Treatment of Lupus
- (2016) Masayuki Mizui et al. Current Rheumatology Reports
- Development of next generation of therapeutic IFN-α2b via genetic code expansion
- (2015) Bo Zhang et al. Acta Biomaterialia
- Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
- (2015) Aixin Yu et al. DIABETES
- Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
- (2015) Jamie B. Spangler et al. IMMUNITY
- Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
- (2015) Suman Mitra et al. IMMUNITY
- Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
- (2014) Johan J.F. Verhoef et al. DRUG DISCOVERY TODAY
- Klebsiella pneumoniae Alleviates Influenza-Induced Acute Lung Injury via Limiting NK Cell Expansion
- (2014) J. Wang et al. JOURNAL OF IMMUNOLOGY
- A general approach to site-specific antibody drug conjugates
- (2014) Feng Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
- (2013) T. Carmenate et al. JOURNAL OF IMMUNOLOGY
- Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents
- (2012) Ricardo P Garay et al. Expert Opinion on Drug Delivery
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Strain-Promoted Alkyne-Azide Cycloadditions (SPAAC) Reveal New Features of Glycoconjugate Biosynthesis
- (2011) Ngalle Eric Mbua et al. CHEMBIOCHEM
- State of the art in PEGylation: The great versatility achieved after forty years of research
- (2011) Gianfranco Pasut et al. JOURNAL OF CONTROLLED RELEASE
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
- (2011) David Saadoun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimized clinical performance of growth hormone with an expanded genetic code
- (2011) H. Cho et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester
- (2009) Michael Miksa et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells
- (2009) David V. Liu et al. JOURNAL OF IMMUNOTHERAPY
- Genetic Encoding and Labeling of Aliphatic Azides and Alkynes in Recombinant Proteinsviaa Pyrrolysyl-tRNA Synthetase/tRNACUAPair and Click Chemistry
- (2009) Duy P. Nguyen et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery
- (2008) Tomoki Ito et al. IMMUNITY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now